Larval zebrafish anaesthesia: match agent to endpoint

Making a zebrafish larva motionless does not, by itself, demonstrate suitable anaesthesia. An agent may abolish a touch response while substantially changing brain activity, blood flow or the behaviour under investigation. A 2026 comparative study assessed six compounds in Danio rerio larvae using behavioural tests, functional brain imaging and cardiovascular measurements. Its practical message is that anaesthetic choice should begin with the required depth and the scientific variable that must be preserved, rather than with historical preference for one familiar drug.

Six agents and several dimensions of anaesthesia

The study compared 2-phenoxyethanol, benzocaine, etomidate, tricaine methanesulfonate or MS-222, isoeugenol and quinaldine sulfate. The investigators first exposed larvae to concentration ranges for 15 minutes. They defined effectiveness through loss of response to tactile stimulation and tolerability through recovery after transfer to anaesthetic-free water.

All six agents could induce loss of a touch response. They were not otherwise equivalent. The margins between an effective concentration and the highest tested non-lethal concentration differed, as did effects on brain, heart and swimming. At high concentrations, every compound except benzocaine within the explored range could be lethal. These experimental results are therefore neither a clinical dose chart nor permission to transfer concentrations directly to another strain, age or system.

Animal welfare and data validity require the same discipline: teams should define what they mean by sedation, immobilisation or deep anaesthesia, specify the stimulus used to assess responsiveness and document recovery to a state compatible with the next stage of the protocol.

Immobility does not preserve every scientific endpoint

In vivo calcium imaging followed activity across brain regions in transgenic larvae at four days post-fertilisation. At the highest concentrations, 2-phenoxyethanol, benzocaine and isoeugenol broadly reduced the neuronal signal. MS-222 and quinaldine sulfate also produced depression consistent with deep anaesthesia. Etomidate affected activity in a different, more limited pattern than agents producing the broadest suppression.

That comparison matters for functional imaging. A weak brain signal may reflect the intended depth of anaesthesia, but it may also erase the biological response that the experiment was designed to detect. A preparation that remains stable under a microscope is not automatically a valid preparation. Protocols should separate the mechanical or pharmacological immobilisation required for acquisition, the intended anaesthetic depth and the compound’s own effect on the system being measured.

The authors also measured atrial and ventricular beat rates, blood flow and blood velocity. All agents reduced heart rate at their highest concentrations. Five compounds also produced concentration-dependent decreases in flow and velocity. Etomidate showed relative preservation of surrogate stroke volume and calculated cardiac output under the tested conditions. This makes it a potentially useful option when cardiovascular function is the endpoint, not a universal choice for every procedure.

Aversion adds another refinement criterion

A separate experiment placed groups of ten 4.5-day-old larvae in an arena where a compound entered one side and its control entered the other. Nine groups were tested per compound. Among the six anaesthetics, only 0.1 mM quinaldine sulfate prompted avoidance resembling the expected response to the positive control. The result indicates aversion in this design before movement was lost.

Failure to detect avoidance for the other five agents does not establish the absence of a negative experience. The assay captures a short-term spatial response in mobile larvae at one developmental stage and in one arena. It complements rather than replaces swimming observations, tactile responses, brain activity, physiology and recovery. No single measure should stand in for the whole welfare assessment.

The study identifies MS-222 and quinaldine sulfate as the most suitable of the tested agents and concentrations for producing deep anaesthesia. That ranking must be read alongside quinaldine’s aversive effect and the cardiovascular findings. Effectiveness is not the same as optimal welfare, nor does it mean neutrality across all measurements.

Build the decision matrix before the experiment

Research facilities can translate the evidence into a decision matrix. The first column should state the aim: reduced movement, immobilisation for imaging, a potentially nociceptive procedure, cardiac measurement, behavioural observation or euthanasia. Further columns should record developmental stage, exposure duration, solvent and solvent control, depth criteria, endpoints likely to be disturbed, recovery method and stopping rules.

Only then should the team select the agent and concentration. A pilot study can test induction time, between-larva variability, stability across the acquisition window and return of observable functions. Lot, age in hours or days post-fertilisation, temperature, pH, solution preparation and actual contact time should be traceable. A vehicle control is essential when the agent requires a solvent.

Validation must include the scientific result. A cardiovascular study should establish that the anaesthetic does not dominate the expected effect. A neural imaging study should quantify the compound’s impact on baseline signal and stimulus responses. A behavioural study should avoid confusing residual sedation or motor impairment with a change in the state of interest. Anaesthesia then becomes a declared experimental variable rather than a procedural footnote.

Governance should link the matrix to staff competence and approved procedures. The person preparing the bath, the observer assessing depth and the person authorising an early stop need defined roles. Deviations, delayed recovery and unexpected mortality should trigger review of the full chain, including water parameters and preparation error, rather than an immediate assumption that the nominal concentration alone explains the event.

Limits and appropriate scope

Most experiments used larvae at four to 4.5 days post-fertilisation and short exposures. They cannot define a protocol for adults, other species, repeated exposure or invasive procedures. Internal compound concentrations varied substantially relative to bath concentrations, showing that nominal exposure does not directly describe absorbed dose.

A 2021 randomised study in adult AB zebrafish compared different protocols and followed recovery for one hour. It addresses a separate question and demonstrates why larval findings cannot simply be extended to adults. FELASA recommendations on humane killing of laboratory fish likewise stress that species, developmental stage, water conditions, aversion and intended sample use all belong in local validation.

Loss of tactile response does not on its own prove an absence of perception. Calcium imaging reports neuronal activity, but the authors do not define an activity threshold that would demonstrate loss of consciousness. The study also focuses on immediate effects and does not characterise every delayed consequence for development, physiology or future experimental phenotypes.

These data therefore support refinement, not a recipe. Each institution must integrate anaesthetic choice into its ethical review, authorised procedures and scientific question. Local governance should approve changes before implementation, and results from larval zebrafish should not be converted into general fish guidance.

Select by purpose and verify with data

The study shows why popularity is not sufficient grounds for selecting an agent. MS-222 and quinaldine sulfate can produce deep anaesthesia under the tested conditions, but quinaldine prompted avoidance. Etomidate better preserved selected cardiovascular measures without meeting every other objective. Effects on brain, heart and behaviour need to be anticipated during study design.

Vetofish can support research facilities in reviewing anaesthesia procedures, designing pilot comparisons, defining induction and recovery criteria and identifying confounding variables. The purpose is to document a choice proportionate to developmental stage and scientific endpoint, without turning a comparative experiment into a universal protocol.